Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT06193473 |
| Other study ID # |
Pharm. Role in Cardiology |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
November 30, 2021 |
| Est. completion date |
November 30, 2022 |
Study information
| Verified date |
January 2024 |
| Source |
Bezmialem Vakif University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Clinical pharmacy services aim to enhance patient outcomes and reduce the risk of potential
drug-related harm by offering patient-centred pharmaceutical care. In the hospital setting,
clinical pharmacists collaborate with physicians as part of a multidisciplinary team to
identify and prevent DRPs (Drug-related problems). Clinical pharmacist interventions
encompass 'any action initiated by a pharmacist that directly results in patient management
or a modification in medication.' The favourable clinical and economic impacts of
interventions have been well-established for decades. Clinical pharmacists have played an
important role in ensuring the effective and correct use of medicines in many settings.
This study aims to investigate the clinical pharmacy services provided by clinical
pharmacists to patients receiving antithrombotic therapy. For this study, patients were
divided into two groups: a control group and an intervention group. A comprehensive
medication review will be conducted by the clinical pharmacist for both the control and
intervention groups. Drug-related problems such as drug selection, dose errors, possible
drug-drug interactions, and inappropriate drug use, will be identified. In the control group,
no interventions will be made by the clinical pharmacist. In the intervention group, solution
recommendations for identified and clinically significant issues will be presented to the
physician, and the provided services will be documented. Furthermore, the groups will be
evaluated for whether there are any hospital readmissions within 1 and 3 months following
discharge for the patients.
Description:
Patients with cardiovascular disease are at significant risk for adverse drug events and
medication errors. Moreover, the rate of use of high-risk drugs such as antithrombotic drugs
is higher in these patients. In the literature, antithrombotics have been shown as one of the
main causes of adverse drug events and drug-related hospitalizations. Therefore, follow-up of
patients treated with antithrombotics is very important. Guideline-based therapy
significantly reduces the risk of all-cause and cardiovascular (CV) death. Multidisciplinary
antithrombotic management can play an important role in increasing prescribing physicians'
adherence to guidelines. Effective interventions such as medication review, establishment of
treatment protocols, education, and medication reconciliation at hospitalization and
discharge can help increase adherence to the guideline. In patients receiving antithrombotic
therapy, individual evaluation of drug therapy suitability, formulation of a drug treatment
plan, dose adjustment, drug monitoring, detection and prevention of clinically important
drug-drug interactions, and antithrombotic transition protocols should be considered. Such
interventions must appropriately balance each individual's risk of thromboss and bleeding.
Pharmacists are recognized as leading healthcare professionals in detecting, resolving, and
preventing DRPs. Assessments of the quality and value of pharmacist interventions remain
crucial for the development of new pharmaceutical care services and for enhancing our
understanding of the frequency and variety of DRPs observed in various clinical settings. The
literature has demonstrated the impact of Clinical Pharmacy Services on cardiovascular
patients. Collaborating with a clinical pharmacist during inpatient treatment has been shown
to improve medication adherence, reduce adverse drug reactions, and minimize medication
errors post-discharge. The benefits of these pharmacist-led services in reducing
hospitalization and healthcare costs were emphasized. Clinical pharmacy services have
contributed to an enhancement in healthcare quality without compromising patient well-being.
Pharmacists can take on the responsibility of antithrombotic management, ensuring that
patients receive the right medication, in the correct dosage, and for the appropriate
duration from the initial consultation to outpatient follow-up. Increasing the continuity of
pharmaceutical care will enhance patient outcomes and reduce costs.
In this study, two groups were established as control group and intervention group. In the
control group, no interventions will be made by the Clinical Pharmacist. Within the
intervention group, patient characteristics such as the length of hospital stay, reason for
hospitalization, underlying conditions, and the appropriateness of prescribed medications
were evaluated for the patients who received antithrombotic treatment and met the inclusion
criteria. Through medication reviews, evaluations were made to identify drug-related problems
and provide solutions to these problems. The clinical pharmacist provided recommendations to
the physicians regarding significant clinically important problems. Additionally, follow-up
was performed to determine whether the patients had a re-admission within 3 months.
